Use of Cinacalcet HCL (MIMPARA®/SENSIPAR®) to control mineral metabolism in patients with end-stage renal disease (ESRD) on dialysis complicated by secondary hyperparathyroidism (SHPT):: A cost-consequence analysis of Cinacalcet HCL versus standard of care (SC)

被引：0
|
作者：
Perrault, Louise [1 ]
Carter, Dave [1 ]
Molemans, Bart [1 ]
Maetzel, Andreas [1 ]
机构：
[1] Amgen Europe GmbH, Zug, Switzerland
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：136 / 136
页数：1
相关论文
共 3 条
  • [1] The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective
    Garside, Ruth
    Pitt, Martin
    Anderson, Rob
    Mealing, Stuart
    D'Souza, Richard
    Stein, Ken
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (05) : 1428 - 1436
  • [2] The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation
    Garside, R.
    Pitt, M.
    Anderson, R.
    Pitt, M.
    Anderson, R.
    Mealing, S.
    Roome, C.
    Snaith, A.
    D'Souza, R.
    Welch, K.
    Stein, K.
    HEALTH TECHNOLOGY ASSESSMENT, 2007, 11 (18) : 1 - +
  • [3] Use of cinacalcet to reduce complications associated with uncontrolled bone mineral metabolism in patients with end-stage renal disease on hemodialysis: A cost-effectiveness analysis
    Maetzel, Andreas
    Roze, Stephan
    Stolshek, Bradley
    Cangialose, Charles
    Valentine, William J.
    Perrault, Louise
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 135 - 135
1